Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
In the 1966 novel, Fantastic Voyage, written by biochemist and author Isaac Asimov, a crew of people become miniaturized in order to travel through the body of a scientist and save him from a blood clot in his brain.
Mucus and other airway secretions that are expelled when a person with the flu coughs or exhales appear to protect the virus when it becomes airborne, regardless of humidity levels, a creative experiment conducted by the University of Pittsburgh and Virginia Tech discovered.
Georgetown University Medical Center (GUMC) professors offer expertise for journalists seeking interviews in a variety of subjects related to Ebola.
Influenza vaccines that better target the influenza surface protein called neuraminidase (NA) could offer broad protection against various influenza virus strains and lessen the severity of illness, according to new research published in Cell.
Seasonal flu deaths have been studied and it has been seen that since 2009, over the six seasons of flu with the H1N1 strain of the virus, children under 2 years of age are most likely to succumb. Less than one third of these babies that died had received a vaccination against the flu virus.
Continuous low doses of far ultraviolet C light can kill airborne flu viruses without harming human tissues, according to a new study at the Center for Radiological Research at Columbia University Irving Medical Center.
Researchers have developed a universal vaccine to combat influenza A viruses that produces long-lasting immunity in mice and protects them against the limitations of seasonal flu vaccines, according to a study led by Georgia State University.
People with higher levels of antibodies against the stem portion of the influenza virus hemagglutinin protein have less viral shedding when they get the flu, but do not have fewer or less severe signs of illness, according to a new study published in mBio.
This year's influenza outbreak is already the most widespread on record since health officials began keeping track about a dozen years ago, with millions of Americans being infected by emerging and current strains such as the dominant H3N2.
Alphabet’s venture arm called Google Ventures earlier is one of the supporters of a mega projects that is developing a vaccine for flu that is safe and effective. Vaccitech from United Kingdom is working towards development of the vaccine and Alphabet has shown its support by contributing $27.6 million in new funding. The funds would be used conduct clinical trials and try the new vaccine.
Acute respiratory tract infections (ARTI) are the leading global cause of death in early childhood, according to the Centers for Disease Control and Prevention.
As flu season picks up steam across the country, it's important for people to be tested very early after symptoms that are compatible with influenza start, since there are effective treatments that can limit severe, life-threatening disease and curtail transmission to others.
Unigloves new Fortified single use gloves incorporate silver ion technology from BioCote, which has been scientifically proven to destroy 90% of harmful bacteria within just 15 minutes and 99.5% in only two hours.
Lactic acid bacteria, commonly used as probiotics to improve digestive health, can offer protection against different subtypes of influenza A virus, resulting in reduced weight loss after virus infection and lower amounts of virus replication in the lungs, according to a study led by Georgia State University.
Experts at the University of Warwick have produced microscopic footage of the potentially deadly E. coli bacteria being wiped out in just two hours on an antimicrobial treated ‘intelligent’ surface.
Researchers at Johns Hopkins Bloomberg School of Public Health have discovered a genetic mutation in the FluMist intranasal flu vaccine that has the potential to be altered to enhance the vaccine's protective effect.
A collaborative research and development partnership between researchers at the University of Georgia and Sanofi Pasteur, the largest influenza vaccine manufacturer in the world, has resulted in the identification of a vaccine candidate that protects against multiple co-circulating strains of H3N2 influenza isolated over five seasons following testing in mouse and ferret models.
Each year, public health officials monitor the spread of influenza to identify which flu strains need to go into that year's vaccines and where outbreaks will occur. But it can be difficult to predict how bad a particular flu season will be until people actually start getting sick.
There has been a fear that the swine flu vaccine, Pandemrix, would increase the risk of autoimmune diseases other than narcolepsy.
With breaking news of a more severe Aussie Flu strain heading for the UK, there is a British technology that provides the ultimate surface protection against the virus - reducing it by 99.99%!